Developing a risk assessment tool to identify HIV-uninfected adolescent girls and young women at highest risk for HIV infection: a key step for targeted biomedical HIV prevention

开发风险评估工具来识别艾滋病毒感染风险最高的未感染艾滋病毒的少女和年轻妇女:有针对性的生物医学艾滋病毒预防的关键步骤

基本信息

  • 批准号:
    10252155
  • 负责人:
  • 金额:
    $ 23.33万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Background: In sub-Saharan Africa (SSA), adolescent girls and young women (AGYW) 15-24 years of age remain at epicenter of the HIV epidemic, with more than 270,000 new HIV infections each year. Biomedical HIV prevention strategies like tenofovir-based oral pre-exposure prophylaxis (PrEP) are promising measures for reducing HIV acquisition in AGYW. However, providing PrEP to all 100 million AGYW in SSA is not feasible, economical, or necessary, as the risk of HIV acquisition among AGYW is not uniformly high. Risk assessment tools are needed to identify those AGYW sub-populations at greatest risk for acquiring HIV in order to support targeted PrEP program implementation. Existing risk assessment tools for HIV incidence in AGYW have had important limitations surrounding feasibility, validity, and generalizability. The primary goal of this project is to develop a regional risk assessment tool for AGYW that is feasible to implement, valid, and generalizable. Our overarching premise is that risk of HIV acquisition among AGYW is not uniform and it is possible to identify high risk AGYW at a regional level. Aims and Methods: Using nationally representative data from 13 African countries collected as part of the Population-based HIV Impact Assessment (PHIA) initiative, our team will address this premise through three specific aims. In the first aim, we will explore risk factors associated with recent HIV infection, a marker of incident HIV, among AGYW. Recent infection is defined in the PHIA data using a well-established testing algorithm. Using data from 13 PHIA surveys from 2015-2019, which include >50,000 observations, individual, structural, household, and epidemiologic predictors of recent HIV infection among AGYW will be identified. In the second aim, we will use the candidate predictors from the first aim to develop and internally validate a risk assessment tool to identify AGYW at highest risk of HIV acquisition. In the third aim, we will externally validate the risk assessment tool in five second-round PHIA surveys from 2020. Team: The team, led by an early-career Principal Investigator, has expertise in HIV prevention for AGYW, biomedical HIV prevention, risk score development, and advanced methods for complex survey data. The team is supported by a technical advisory panel of experts from multiple SSA regions. Expected Impact: These findings will provide an in-depth understanding of the current transmission dynamics of HIV among AGYW in SSA. At the end of the study, we expect to have a validated clinical risk assessment tool that can be applied to a range of SSA settings. Such a tool has the potential to transform the clinical delivery of PrEP and other biomedical HIV prevention strategies in SSA.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nora Rosenberg其他文献

Nora Rosenberg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nora Rosenberg', 18)}}的其他基金

Developing a regionally representative risk assessment tool to identify men at highest risk of HIV acquisition in sub-Saharan Africa
开发具有区域代表性的风险评估工具,以确定撒哈拉以南非洲地区感染艾滋病毒风险最高的男性
  • 批准号:
    10762645
  • 财政年份:
    2023
  • 资助金额:
    $ 23.33万
  • 项目类别:
Developing a risk assessment tool to identify HIV-uninfected adolescent girls and young women at highest risk for HIV infection: a key step for targeted biomedical HIV prevention
开发风险评估工具来识别艾滋病毒感染风险最高的未感染艾滋病毒的少女和年轻妇女:有针对性的生物医学艾滋病毒预防的关键步骤
  • 批准号:
    10375594
  • 财政年份:
    2021
  • 资助金额:
    $ 23.33万
  • 项目类别:
Enhancing HIV assisted contact tracing in Malawi through blended learning: An Implementation Science Study
通过混合学习加强马拉维艾滋病毒辅助接触者追踪:一项实施科学研究
  • 批准号:
    10082594
  • 财政年份:
    2020
  • 资助金额:
    $ 23.33万
  • 项目类别:
Enhancing HIV assisted contact tracing in Malawi through blended learning: An Implementation Science Study
通过混合学习加强马拉维艾滋病毒辅助接触者追踪:一项实施科学研究
  • 批准号:
    10222533
  • 财政年份:
    2020
  • 资助金额:
    $ 23.33万
  • 项目类别:
Enhancing HIV assisted contact tracing in Malawi through blended learning: an implementation science study
通过混合学习加强马拉维艾滋病毒辅助接触者追踪:一项实施科学研究
  • 批准号:
    10599580
  • 财政年份:
    2020
  • 资助金额:
    $ 23.33万
  • 项目类别:
Enhancing HIV assisted contact tracing in Malawi through blended learning: An Implementation Science Study
通过混合学习加强马拉维艾滋病毒辅助接触者追踪:一项实施科学研究
  • 批准号:
    10873493
  • 财政年份:
    2020
  • 资助金额:
    $ 23.33万
  • 项目类别:
Enhancing HIV assisted contact tracing in Malawi through blended learning: An Implementation Science Study
通过混合学习加强马拉维艾滋病毒辅助接触者追踪:一项实施科学研究
  • 批准号:
    10626785
  • 财政年份:
    2020
  • 资助金额:
    $ 23.33万
  • 项目类别:
Enhancing HIV assisted contact tracing in Malawi through blended learning: An Implementation Science Study
通过混合学习加强马拉维艾滋病毒辅助接触者追踪:一项实施科学研究
  • 批准号:
    10405504
  • 财政年份:
    2020
  • 资助金额:
    $ 23.33万
  • 项目类别:
Developing and Assessing a Male Engagement Intervention for Option B+ in Malawi
在马拉维制定和评估选项 B 的男性参与干预措施
  • 批准号:
    8846733
  • 财政年份:
    2015
  • 资助金额:
    $ 23.33万
  • 项目类别:
Developing and Assessing a Male Engagement Intervention for Option B+ in Malawi
在马拉维制定和评估选项 B 的男性参与干预措施
  • 批准号:
    9025583
  • 财政年份:
    2015
  • 资助金额:
    $ 23.33万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 23.33万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 23.33万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 23.33万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 23.33万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 23.33万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 23.33万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 23.33万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 23.33万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 23.33万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 23.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了